IMMUNIC INC (IMUX:NASDAQ)
$14.64 -0.13 (-0.8802%)
Analysed IMMUNIC INC (IMUX:NASDAQ) News Sources
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?
17-05-2026
yahoo.com
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
19-05-2026
yahoo.com
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
19-05-2026
proactiveinvestors.com
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
27-05-2026
yahoo.com
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
27-05-2026
yahoo.com
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
27-05-2026
proactiveinvestors.com
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
28-05-2026
yahoo.com
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
28-05-2026
proactiveinvestors.com
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10-06-2026
yahoo.com
Immunic to Participate in Investor Conferences in July
09-07-2026
yahoo.com
What is the current price of IMMUNIC INC (IMUX:NASDAQ)?
The current price of IMMUNIC INC (IMUX:NASDAQ) is $14.64.
IMMUNIC INC (IMUX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNIC INC (IMUX:NASDAQ) since the previous trading day is $-0.13.
IMMUNIC INC (IMUX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNIC INC (IMUX:NASDAQ) since the previous trading day is -0.8802%.
What is the most recent average sentiment score for IMMUNIC INC (IMUX:NASDAQ)?
The most recent average sentiment score for IMMUNIC INC (IMUX:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for IMMUNIC INC (IMUX:NASDAQ)?
The most recent sentiment for IMMUNIC INC (IMUX:NASDAQ) is .
SEC-8K** Filing Available For IMMUNIC INC (IMUX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.